NCT04823585View on ClinicalTrials.gov

Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)

PHASE4CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

January 16, 2025

Study Completion Date

January 16, 2025

Conditions
Asthma, Aspirin-InducedChronic Rhinosinusitis with Nasal Polyps
Interventions
DRUG

Mepolizumab

Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.

DRUG

Placebo

Solution. Subcutaneous.

Trial Locations (1)

00029

Helsinki University Hospital, Helsinki

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER

NCT04823585 - Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) | Biotech Hunter | Biotech Hunter